| 000 | 01136 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250513091917.0 | ||
| 264 | 0 | _c19960808 | |
| 008 | 199608s 0 0 eng d | ||
| 022 | _a0160-6689 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSuppes, T | |
| 245 | 0 | 0 |
_aMedication optimization during clozapine treatment. _h[electronic resource] |
| 260 |
_bThe Journal of clinical psychiatry _cJul 1996 |
||
| 300 |
_a307-8 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 |
_a1-Naphthylamine _xanalogs & derivatives |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aClozapine _xadverse effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLithium _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aObsessive-Compulsive Disorder _xchemically induced |
| 650 | 0 | 4 |
_aPsychotic Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aSelective Serotonin Reuptake Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aSertraline |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aValproic Acid _xtherapeutic use |
| 700 | 1 | _aRush, A J | |
| 773 | 0 |
_tThe Journal of clinical psychiatry _gvol. 57 _gno. 7 _gp. 307-8 |
|
| 999 |
_c8664880 _d8664880 |
||